For patients with nonvalvular atrial fibrillation (AFib), taking a direct oral anticoagulant (DOAC) instead of warfarin may cut the risk of dementia by 15 to 20 percent, according to a large database study published Nov. 2 in the Journal of the American Heart Association.

Climbing rates of violent crime could trigger blood pressure (BP) spikes within nearby communities—particularly among individuals living in what are considered “safe” neighborhoods—according to a study of 50,000 adults living in Chicago.

Poor health literacy could mean an increased risk of death for patients hospitalized with acute decompensated heart failure (ADHF), according to a study published in Mayo Clinic Proceedings Nov. 7.

Medtronic announced U.S. Food and Drug Administration (FDA) approval to begin a clinical trial to evaluate the Symplicity Spyral renal denervation system in patients with high blood pressure (hypertension) who are already prescribed anti-hypertension medications.

Roux-en-Y gastric bypass (RYGB) is linked to greater weight loss compared to two other bariatric procedures but also the highest risk of adverse events in the short term, researchers reported in the Annals of Internal Medicine.

Inhibiting a certain class of cyclin-dependent kinase (CDK) proteins could protect cancer patients from chemotherapy-induced heart failure—the second leading cause of death in the demographic after cancer recurrence—according to research published in the Journal of Biological Chemistry.

Medtronic data presented today reinforce the durability, safety, and effectiveness of the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral artery disease (PAD) in the superficial femoral (SFA) and popliteal arteries.

Boston Scientific announced clinical outcomes from the IMPERIAL Long Lesion Sub-study demonstrating that the Eluvia Drug-Eluting Vascular Stent System is safe and effective in treating patients with long, complex, calcified lesions within the superficial femoral and proximal popliteal arteries.